Rapid Micro Biosystems to Participate in KeyBanc Capital Markets Healthcare Forum
Rhea-AI Summary
Rapid Micro Biosystems (Nasdaq: RPID) will participate in the KeyBanc Capital Markets Healthcare Forum with a virtual Q&A on March 17, 2026 at 11:15 a.m. ET. A live webcast will be available on the company's investor relations site and will be archived for later replay.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
Momentum scanner shows peers like RCEL and ARAY moving up, but sector_momentum is flagged as company-specific and the target’s direction is unspecified, indicating this headline is not part of a broad sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 26 | Conference participation | Neutral | -3.1% | Announcement of TD Cowen healthcare conference presentation and webcast details. |
| Feb 24 | Earnings timing | Neutral | +6.3% | Scheduling of Q4 and full-year 2025 results release and webcast. |
| Feb 12 | Equity inducement | Neutral | +2.8% | Inducement RSUs and options granted to new employees under Nasdaq rules. |
| Jan 13 | Prelim revenue | Positive | +21.1% | Record preliminary unaudited Q4 and 2025 revenue and system placements. |
| Jan 07 | Conference participation | Neutral | -1.2% | Notice of J.P. Morgan Healthcare Conference presentation and webcast. |
Recent RPID news has included multiple conference appearances and one strong preliminary revenue update. Price reactions have ranged from modest moves around conference and administrative updates to a sharp 21.05% gain on record preliminary 2025 revenue, suggesting investors respond most strongly to concrete financial performance disclosures.
Over the last few months, Rapid Micro Biosystems has issued a mix of conference participation notices, administrative updates, and a key preliminary revenue release. The company reported record unaudited Q4 and full‑year 2025 revenue on Jan 13, 2026, which saw the stock rise 21.05%. Other items, such as inducement grants and conference/webcast announcements, produced smaller price moves in both directions. Today’s KeyBanc forum participation fits the pattern of communication-focused updates rather than a new financial or clinical catalyst.
Market Pulse Summary
This announcement highlights Rapid Micro Biosystems’ participation in the KeyBanc Capital Markets Healthcare Forum on March 17, 2026, with a virtual Q&A at 11:15 a.m. ET and an archived webcast. It fits a pattern of regular investor-engagement events alongside prior conference appearances. Investors may focus on how this forum complements upcoming milestones, such as the scheduled fourth quarter and full‑year 2025 results release and recent preliminary revenue disclosure.
Key Terms
webcast technical
AI-generated analysis. Not financial advice.
LEXINGTON, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that the Company will participate in the KeyBanc Capital Markets Healthcare Forum.
The Company is scheduled to participate in a virtual question and answer session with the host analyst on Tuesday, March 17, 2026, at 11:15 a.m. Eastern Time. A live webcast will be available on the Rapid Micro Biosystems investor relations website at https://investors.rapidmicrobio.com/ and can be accessed here. The webcast will be archived and available for replay after the event.
About Rapid Micro Biosystems
Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company’s flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control (“MQC”) testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct system brings the quality control lab to the manufacturing floor, unlocking the power of MQC automation to deliver the faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that customers rely on to ensure safe and consistent supply of important healthcare products. The Company is headquartered Lexington, Massachusetts, and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Switzerland, Germany, and the Netherlands. For more information, please visit www.rapidmicrobio.com or follow the Company on X (formerly known as Twitter) at @rapidmicrobio or on LinkedIn.
Investor Contact: Michael Beaulieu, CFA Vice President, Investor Relations and Corporate Communications mbeaulieu@rapidmicrobio.com Media Contact: media@rapidmicrobio.com
FAQ
When will Rapid Micro Biosystems (RPID) present at the KeyBanc Healthcare Forum?
How can investors watch the RPID KeyBanc Healthcare Forum webcast?
Will the Rapid Micro Biosystems KeyBanc session be interactive for questions?
What topics will Rapid Micro Biosystems (RPID) likely cover at the forum?
Where will the archived replay of the RPID KeyBanc presentation be available?
